News

A study published in the British Journal of Psychiatry argues that people who are shorter have a higher risk of developing dementia — an increased risk that is particularly found in men. According to the study’s author, being short does not cause dementia, but how tall a person is could…

Anavex Life Sciences Corp. will initiate a Phase 2a clinical trial for the treatment of Alzheimer’s disease with their compounds – ANAVEX 2-73 and ANAVEX PLUS – after receiving regulatory approval by the Ethics Committee in Australia. ANAVEX 2-73, an orally available drug candidate, is under investigation to treat…

In a study published in the online issue of Molecular Neurodegeneration journal, a team of researchers at Georgetown University Medical Center (GUMC), in collaboration with researchers at the Capital Medical University in Beijing, China and funded by Merck Research Laboratories, shows that Tau protein is the key triggering event to…

A multi-institutional team of British researchers has determined that evidence suggests a high prevalence of comorbid medical conditions and related complaints among people with dementia, and that the presence of dementia may complicate clinical care for other conditions, and undermine a patient’s ability to manage a chronic condition. The…

Second Wind Dreams®, an Atlanta-based international non-profit organization for the gerontological population, is set to present its flagship program Virtual Dementia Tour (VDT®) next week, Thursday, November 6 in New York City. This year’s event is in commemoration of the organization’s National Take the Tour Day, which began in 2013 as a…

In a recent study published in the online version of Journal of Biological Chemistry scientists reported to have found a new target molecule that will help the fight against Alzheimer’s disease. The study is entitled, “The Spleen Tyrosine Kinase (syk) Regulates Alzheimer’s Aβ Production and Tau…

A group of investigators from the University of Melbourne, Australia recently developed a simple blood test that could very well change the future of diagnosing Alzheimer’s Disease, and may ultimately be a driving force behind the improvement of patient outcomes, as it allows earlier detection of this…

TauRx Therapeutics Ltd, a spin-off company from the University of Aberdeen in Scotland, recently hosted a breakfast event to inform both patients and caregivers about their phase III clinical trial, which will test a treatment for behavioral variant Frontotemporal Dementia (bvFTD), and is currently enrolling participants. The “Meet the Experts” breakfast was held on …

The Alzheimer’s Association is awarding a new series of grants to support research on non-drug therapies for the treatment of Alzheimer’s disease as a way of advancing the search for a cure for the condition and meeting the needs of projects that are not funded either…

Caption: Amyloid plaques are found in the brains of people with Down syndrome and Alzheimer’s disease.Credit: Juan Gartner A study entitled “SortingNexin 27 Regulates Aβ Production through Modulatingγ-Secretase Activity” published in the online issue of Cell Reports reveals common molecular mechanisms between…